Three major hospital systems—Mount Sinai in New York, University of Michigan Health and Sparrow Hospital, and the University of Kansas Hospital Authority—have filed lawsuits accusing CVS Health and its subsidiaries of operating a secret scheme that allegedly diverted hundreds of millions of dollars in drug savings away from hospitals serving vulnerable and uninsured patients [1]. The lawsuits claim that CVS manipulated reimbursements tied to the federal 340B Drug Pricing Program, keeping the difference as profit through affiliated companies such as CaremarkPCS, CVS Specialty, Caremark LLC, and WellPartner [1].
According to the complaints, Mount Sinai alleges losses exceeding $121 million since 2020, University of Michigan and Sparrow report more than $66 million in losses, and University of Kansas Hospital Authority claims nearly $62 million in losses [1]. The lawsuits detail that insurers and patients paid full price for specialty drugs, but CVS later reduced payments to hospitals, with the difference retained as profit. One cited example involves the specialty drug Stelara, where a prescription generated over $24,000 for the University of Michigan’s specialty pharmacy but only about $18,000 when processed through CVS Specialty, resulting in a $6,523.18 'spread' allegedly pocketed by CVS [1].
The federal 340B Drug Pricing Program allows qualifying hospitals to purchase expensive medications at discounted prices, with the intent that savings are used to fund community health services such as free care for uninsured patients, free vaccines, mental health clinics, and medication management programs [1]. The hospitals allege that CVS’s actions undermine these community benefits by diverting funds intended for patient care [1].
A CVS spokesperson stated, 'We do not comment on matters that are subject to ongoing litigation and remain focused on serving our customers and executing our business priorities' [1]. No market reaction or analyst opinions are provided in the article [1].
CONCLUSION
The lawsuits by major hospital systems against CVS Health allege significant financial harm and diversion of funds intended for vulnerable patient care under the 340B program. With losses claimed in the hundreds of millions and accusations of a secret pricing scheme, the litigation poses a potentially high-impact risk for CVS. The outcome of these lawsuits could have substantial implications for both CVS and the broader healthcare sector.